ASN

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment,…

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- At the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting in Orlando, the American Kidney Fund (AKF) will present its…

OVERLAND PARK, KS., Nov. 12, 2021 (GLOBE NEWSWIRE) -- New kidney and metabolic research involving George Clinical teams and scientific leaders has received global attention during the…

-Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis- …

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted…

BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301…

Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on…